246 related articles for article (PubMed ID: 38137407)
1. An Overview on Lipid Droplets Accumulation as Novel Target for Acute Myeloid Leukemia Therapy.
Nisticò C; Chiarella E
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137407
[TBL] [Abstract][Full Text] [Related]
2. Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD.
Mashek DG
Mol Metab; 2021 Aug; 50():101115. PubMed ID: 33186758
[TBL] [Abstract][Full Text] [Related]
3. The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways.
Bakhtiyari M; Liaghat M; Aziziyan F; Shapourian H; Yahyazadeh S; Alipour M; Shahveh S; Maleki-Sheikhabadi F; Halimi H; Forghaniesfidvajani R; Zalpoor H; Nabi-Afjadi M; Pornour M
Cell Commun Signal; 2023 Sep; 21(1):252. PubMed ID: 37735675
[TBL] [Abstract][Full Text] [Related]
4. Cancer cells employ lipid droplets to survive toxic stress.
Kostecka LG; Mendez S; Li M; Khare P; Zhang C; Le A; Amend SR; Pienta KJ
Prostate; 2024 May; 84(7):644-655. PubMed ID: 38409853
[TBL] [Abstract][Full Text] [Related]
5. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets.
Mishra SK; Millman SE; Zhang L
Blood; 2023 Mar; 141(10):1119-1135. PubMed ID: 36548959
[TBL] [Abstract][Full Text] [Related]
6. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
Wang A; Zhong H
Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
[TBL] [Abstract][Full Text] [Related]
7. Lipid metabolism in cancer progression and therapeutic strategies.
Fu Y; Zou T; Shen X; Nelson PJ; Li J; Wu C; Yang J; Zheng Y; Bruns C; Zhao Y; Qin L; Dong Q
MedComm (2020); 2021 Mar; 2(1):27-59. PubMed ID: 34766135
[TBL] [Abstract][Full Text] [Related]
8. Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia.
Stuani L; Riols F; Millard P; Sabatier M; Batut A; Saland E; Viars F; Tonini L; Zaghdoudi S; Linares LK; Portais JC; Sarry JE; Bertrand-Michel J
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30366412
[No Abstract] [Full Text] [Related]
9. A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia.
Bolandi SM; Pakjoo M; Beigi P; Kiani M; Allahgholipour A; Goudarzi N; Khorashad JS; Eiring AM
Cells; 2021 Oct; 10(11):. PubMed ID: 34831055
[TBL] [Abstract][Full Text] [Related]
10. Targeting of Mevalonate-Isoprenoid Pathway in Acute Myeloid Leukemia Cells by Bisphosphonate Drugs.
Chiarella E; Nisticò C; Di Vito A; Morrone HL; Mesuraca M
Biomedicines; 2022 May; 10(5):. PubMed ID: 35625883
[TBL] [Abstract][Full Text] [Related]
11. Targeting Lactate Metabolism by Inhibiting MCT1 or MCT4 Impairs Leukemic Cell Proliferation, Induces Two Different Related Death-Pathways and Increases Chemotherapeutic Sensitivity of Acute Myeloid Leukemia Cells.
Saulle E; Spinello I; Quaranta MT; Pasquini L; Pelosi E; Iorio E; Castelli G; Chirico M; Pisanu ME; Ottone T; Voso MT; Testa U; Labbaye C
Front Oncol; 2020; 10():621458. PubMed ID: 33614502
[TBL] [Abstract][Full Text] [Related]
12. Chenodeoxycholic acid suppresses AML progression through promoting lipid peroxidation via ROS/p38 MAPK/DGAT1 pathway and inhibiting M2 macrophage polarization.
Liu J; Wei Y; Jia W; Can C; Wang R; Yang X; Gu C; Liu F; Ji C; Ma D
Redox Biol; 2022 Oct; 56():102452. PubMed ID: 36084349
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
[TBL] [Abstract][Full Text] [Related]
14. A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia.
Aru B; Pehlivanoğlu C; Dal Z; Dereli-Çalışkan NN; Gürlü E; Yanıkkaya-Demirel G
Front Immunol; 2023; 14():1108200. PubMed ID: 36742324
[TBL] [Abstract][Full Text] [Related]
15. Lipid droplets as metabolic determinants for stemness and chemoresistance in cancer.
Royo-García A; Courtois S; Parejo-Alonso B; Espiau-Romera P; Sancho P
World J Stem Cells; 2021 Sep; 13(9):1307-1317. PubMed ID: 34630864
[TBL] [Abstract][Full Text] [Related]
16. Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment.
Tabe Y; Konopleva M
Cancer Drug Resist; 2023; 6(1):138-150. PubMed ID: 37065866
[TBL] [Abstract][Full Text] [Related]
17. Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia.
Magliulo D; Bernardi R; Messina S
Front Oncol; 2018; 8():255. PubMed ID: 30073149
[TBL] [Abstract][Full Text] [Related]
18. [Energy metabolism of acute myeloid leukemia cells in the bone marrow microenvironment].
Tabe Y
Rinsho Ketsueki; 2022; 63(9):1046-1051. PubMed ID: 36198528
[TBL] [Abstract][Full Text] [Related]
19. A distinct lipid metabolism signature of acute myeloid leukemia with prognostic value.
Li D; Liang J; Yang W; Guo W; Song W; Zhang W; Wu X; He B
Front Oncol; 2022; 12():876981. PubMed ID: 35957912
[TBL] [Abstract][Full Text] [Related]
20. Application of synthetic lipid droplets in metabolic diseases.
Zhao P; Zhao Z; Yu Z; Chen L; Jin Y; Wu J; Ren Z
Clin Transl Med; 2023 Nov; 13(11):e1441. PubMed ID: 37997538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
